Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU1 | Q99519 | 14/20 | 0.42 |
| ▸ | NEU4 | Q8WWR8 | 6/20 | 0.42 |
| ▸ | NEU2 | Q9Y3R4 | 10/20 | 0.41 |
| ▸ | NEU3 | Q9UQ49 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21695642 | 0.83 | NEU1 (0.46) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL22731169 | 0.73 | NEU1 (0.37) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL23135680 | 0.73 | NEU1 (0.51) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL12068163 | 0.71 | NEU2 (0.38) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL25060228 | 0.71 | NEU2 (0.38) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL13449503 | 0.71 | NEU2 (0.38) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL17722419 | 0.71 | NEU2 (0.38) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL15227226 | 0.70 | NEU2 (0.37) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL12997167 | 0.70 | NEU2 (0.37) | NEU1NEU4NEU2NEU3 | |
| SCHEMBL10024192 | 0.69 | NEU1 (0.45) | NEU1NEU4NEU2NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152022-A1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152022-A1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, FABP1 | NEU1 1569/4885NEU4 1714/4885NEU2 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.